AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10550565
Drug: Formulation A
RxNorm normalized name: meningococcal vaccine of unknown formulation and unknown serogroups
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation A (reference formulation)
Trial: 2064484
Drug: Standard behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard behavior therapy program
Trial: 6225396
Drug: Oral isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral isotretinoin (0.5 to 1.0 mg/kg/day)
Trial: 26684150
Drug: rhPTH(1‐84) 50
RxNorm normalized name: rhPTH
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rhPTH(1‐84) 50 μg/day, escalated to 75 and then to 100 μg/day if needed
Trial: 19160156
Drug: FAPC for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAPC for additional treatment of bleeding from the main gastroepiploic artery via TGA
Trial: 19160156
Drug: FAPC for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAPC for additional treatment of bleeding from the main gastroepiploic artery via TVA
Trial: 15723023
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with MDD and concurrent SUD symptoms
Trial: 15723023
Drug: Patients without
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients without concurrent SUD symptoms
Trial: 12572379
Drug: Jietongyin Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jietongyin Lotion (JTYL)
Trial: 12572379
Drug: Rishu an
RxNorm normalized name: Aldex AN
DrugBank: Doxylamine (DB00366)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rishu an Lotion (Control)
Trial: 17339867
Drug: Tolterodine 4
RxNorm normalized name: tolterodine 4 mg oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine 4 mg twice daily
Trial: 9467475
Drug: Tolterodine dosages
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine dosages of ≤ 2 mg
Trial: 1978372
Drug: Ipsapirone at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipsapirone at 7.5 mg t.i.d. for 4 weeks
Trial: 356239
Drug: Proquazone (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proquazone (900 mg)
Trial: 356239
Drug: Ibuprofen (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (1200 mg)
Trial: 27481207
Drug: Abatacept (CTLA4-Ig)
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Abatacept (CTLA4-Ig) administered via monthly intravenous infusions for 24 weeks, switched to placebo at 28 weeks, final dose at 52 weeks.
Trial: 27481207
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered via monthly intravenous infusions for 24 weeks, switched to abatacept at 28 weeks, final dose at 52 weeks.
Trial: 25841032
Drug: Inhaled dihydroergotamine
RxNorm normalized name: dihydroergotamine Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled dihydroergotamine (DHE)
Trial: 16855921
Drug: Nabilone (1/4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabilone (1/4 - 1 mg/day)
Trial: 10885439
Drug: UVA irradiation
RxNorm normalized name: UVA URSI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UVA irradiation (70% of the individual's predetermined minimal phototoxic dose)
Trial: 8967586
Drug: Ropivacaine 0.5%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.5%, 3 ml (15 mg)
Trial: 8967586
Drug: Ropivacaine 0.75%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.75%, 3 ml (22.5 mg)
Trial: 1457358
Drug: Beta-carotene supplementation
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene supplementation (20 mg d-1)
Trial: 30266608
Drug: Stratified medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stratified medical therapy (intervention group)
Trial: 20660670
Drug: Caspofungin (CAS)
DrugBank: Caspofungin (DB00520)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caspofungin (CAS) 50 mg/day; day 1, 70 mg
Trial: 20660670
Drug: Liposomal amphotericin
RxNorm normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal amphotericin B (LAMB) 3 mg/kg of body weight/day
Trial: 20660670
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CAS and LAMB (CASLAMB)
Trial: 16363196
Drug: Atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10 mg plus 2 g/day chitosan in two divided doses
Trial: 16363196
Drug: Atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10 mg plus placebo
Trial: 7956214
Drug: Desogestrel-containing oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desogestrel-containing oral contraceptive (9-week on, 1-week off regimen)
Trial: 7956214
Drug: Desogestrel-containing oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desogestrel-containing oral contraceptive (traditional regimen)
Trial: 7956214
Drug: Desogestrel-containing oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desogestrel-containing oral contraceptive (both regimens)
Trial: 3575253
Drug: Theophylline-sodium-glycinate solution
RxNorm normalized name: Theophylline Sodium Glycinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline-sodium-glycinate solution administered orally after a standard breakfast (5.6 mg/kg body weight)
Trial: 3575253
Drug: Theophylline-sodium-glycinate solution
RxNorm normalized name: Theophylline Sodium Glycinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline-sodium-glycinate solution administered orally on an empty stomach (5.6 mg/kg body weight)
Trial: 3575253
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of theophylline-sodium-glycinate solution under fasting conditions
Trial: 3575253
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of theophylline-sodium-glycinate solution
Trial: 26218762
Drug: HF10 therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HF10 therapy
Trial: 26568428
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol (CZP) 400 mg at weeks 0, 2, and 4 then 200 mg every 2 weeks (Q2W)
Trial: 20799592
Drug: silymarin (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: silymarin (70 mg x 3/day)
Trial: 16806096
Drug: Atomoxetine (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine (titrated to a maximum dose of 1.8 mg/kg/day) administered once daily for up to 7 weeks
Trial: 12782954
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of metronidazole by mouth in addition to standard care (240 mg gentamicin IM and 100 mg doxycycline twice daily for 7 days)
Trial: 12782954
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in addition to standard care (240 mg gentamicin IM and 100 mg doxycycline twice daily for 7 days)
Trial: 12782954
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of metronidazole
Trial: 10971246
Drug: Heparin-coated circuits
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated circuits (Group 2)
Trial: 8780763
Drug: Warmed local
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warmed local anesthetic solution at 40 degrees C
Trial: 8780763
Drug: Room temperature
RxNorm normalized name: ROOM DEODORIZER POWDER MENTOR #3202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Room temperature local anesthetic solution
Trial: 19710251
Drug: Daily inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily inhaled corticosteroid (ICS) medication adherence
Trial: 12563673
Drug: Anti-TNF-alpha monoclonal
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-TNF-alpha monoclonal antibody
Trial: 11289667
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of fecal anti‐lectin IgA antibodies and serum anti‐LC3 IgG antibodies
Trial: 8422345
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil ethyl ester (K‐85, 5.7 g/day)
Trial: 8422345
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of K‐85 and Lovastatin
Trial: 3722962
Drug: Rifampin (RMP)
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin (RMP) 900 mg once weekly for ten weeks
Trial: 3722962
Drug: Regimen C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen C: daily RMP 600 mg, ethionamide (ETH) 500 mg, and DDS or clofazimine (CLO) 100 mg for six months, followed by six months of daily DDS or CLO
Trial: 3722962
Drug: Regimen D:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen D: identical to regimen C but comprising daily DDS or CLO plus ETH 500 mg during the second semester
Trial: 3722962
Drug: Clofazimine (CLO)
RxNorm normalized name: Clofazimine
DrugBank: Clofazimine (DB00845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clofazimine (CLO) 100 mg daily
Trial: 20375190
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (10 mg for children aged 2-11 months, 20 mg for children aged ≥12 months)
Trial: 16360995
Drug: Non-steroid anti-inflammatory
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-steroid anti-inflammatory (NSAIDs)
Trial: 12610740
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg orally twice daily for 2.5 days
Trial: 10622283
Drug: 3H-paroxetine binding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3H-paroxetine binding after one year's treatment with different drugs
Trial: 10622283
Drug: 3H-paroxetine binding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3H-paroxetine binding before treatment
Trial: 10622283
Drug: 3H-paroxetine binding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3H-paroxetine binding after one year's treatment
Trial: 7668493
Drug: Intravenous fluid
RxNorm normalized name: Intravenous fluid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fluid administration, analgetics, avoidance of oral fluid or food intake in mild acute pancreatitis
Trial: 7668493
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis in severe acute pancreatitis
Trial: 7668493
Drug: Enteral nutrition
RxNorm normalized name: ENTERAL NUTRITION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral nutrition in pancreatitis treatment
Trial: 1719242
Drug: 2 courses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 courses of adjuvant chemotherapy with cis‐platinum, vinblastine and bleomycin
Trial: 1719242
Drug: 4 courses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 courses of adjuvant chemotherapy with cis‐platinum, vinblastine and bleomycin
Trial: 7005780
Drug: High-dose naproxen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose naproxen (1250 mg/day for 5 days)
Trial: 7005780
Drug: Low-dose naproxen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose naproxen (500 mg loading dose, then 750 mg/day for 5 days)
Trial: 31603732
Drug: Photobiomodulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation therapy (PBMT) using two diode lasers with doses of 35.71 J/cm2 and 27.77 J/cm2, applied daily in contact and perpendicular to the skin.
Trial: 27992691
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (MTX plus sulfasalazine plus hydroxychloroquine)
Trial: 19092007
Drug: Buechel‐Pappas (BP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buechel‐Pappas (BP) implant
Trial: 19092007
Drug: Scandinavian Total
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scandinavian Total Ankle Replacement (STAR) implant
Trial: 19092007
Drug: Both BP
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both BP and STAR implants
Trial: 17295587
Drug: 42 mg
RxNorm normalized name: lithium 42 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 42 mg transdermal nicotine replacement (TNR)
Trial: 17295587
Drug: 21 mg
RxNorm normalized name: aspirin 421 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21 mg transdermal nicotine replacement (TNR)
Trial: 17295587
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg transdermal nicotine replacement (TNR)
Trial: 10759625
Drug: ABT‐229 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT‐229 10 mg b.d.
Trial: 10759625
Drug: ABT‐229 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT‐229 5 mg b.d.
Trial: 8724443
Drug: Flunitrazepam 0.50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam 0.50 mg
Trial: 29273692
Drug: Highly-intensive practice
RxNorm normalized name: California intense cedar pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highly-intensive practice (4 hours daily)
Trial: 29273692
Drug: Moderately-intensive practice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderately-intensive practice (2 hours daily)
Trial: 27140929
Drug: Methylphenidate hydrochloride
RxNorm normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate hydrochloride (4-week trial including 2-week placebo and 2-week treatment)
Trial: 27140929
Drug: Methylphenidate hydrochloride
RxNorm normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate hydrochloride (2-week treatment)
Trial: 12240782
Drug: Lansoprazole granules
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole granules in orange juice (180 mL)
Trial: 12240782
Drug: Lansoprazole granules
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole granules in tomato juice (180 mL)
Trial: 12240782
Drug: Intact lansoprazole
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intact lansoprazole capsule with water (180 mL)
Trial: 10707109
Drug: Ivermectin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin (200 micrograms/kg) with diethylcarbamazine (DEC; 6 mg/kg)
Trial: 10707109
Drug: Ivermectin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin (200 micrograms/kg) with albendazole (400 mg)
Trial: 10707109
Drug: DEC (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEC (6 mg/kg) with albendazole (400 mg)
Trial: 2248082
Drug: Moclobemide 100
RxNorm normalized name: moclobemide 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide 100 mg single dose
Trial: 2248082
Drug: Moclobemide 200
RxNorm normalized name: moclobemide
DrugBank: Moclobemide (DB01171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide 200 mg single dose
Trial: 2248082
Drug: Moclobemide 300
RxNorm normalized name: moclobemide 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide 300 mg single dose
Trial: 2248082
Drug: Moclobemide 300
RxNorm normalized name: moclobemide 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide 300 mg 3 times daily for 1 week
Trial: 2248082
Drug: Moclobemide 100
RxNorm normalized name: moclobemide 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide 100 mg 3 times daily for 1 week
Trial: 2248082
Drug: Moclobemide 200
RxNorm normalized name: moclobemide
DrugBank: Moclobemide (DB01171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide 200 mg 3 times daily for 1 week
Trial: 2248082
Drug: Moclobemide 300
RxNorm normalized name: moclobemide 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide 300 mg 3 times daily for 1 week (24 hours after last dose)
Trial: 2248082
Drug: Moclobemide 100
RxNorm normalized name: moclobemide 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide 100 mg 3 times daily in depressed patients
Trial: 6446929
Drug: 2‐methyl histamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2‐methyl histamine (H1‐receptor agonist)
Trial: 6446929
Drug: Chlorpheniramine (H1‐receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpheniramine (H1‐receptor antagonist)
Trial: 6446929
Drug: Dimaprit (H2‐receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dimaprit (H2‐receptor agonist)
Trial: 30655038
Drug: Tirofiban administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirofiban administered at 2 hours after thrombolysis (Group A)
Trial: 30655038
Drug: Tirofiban administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirofiban administered at 2-12 hours after thrombolysis (Group B)
Trial: 30655038
Drug: Tirofiban administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirofiban administered at 12-24 hours after thrombolysis (Group C)
Trial: 22802250
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extract (120 mg twice daily for 15 days)
Trial: 22802250
Drug: Raltegravir alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir alone (400 mg)
Trial: 15351864
Drug: Prophylactic intravenous
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic intravenous unfractionated heparin (continuous infusion of 100 IU/kg/daily)
Trial: 15351864
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline solution (50 ml/daily as a continuous infusion)
Trial: 15351864
Drug: Prophylactic intravenous
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic intravenous unfractionated heparin
Trial: 9727959
Drug: meta-chlorophenylpiperazine (MCPP),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: meta-chlorophenylpiperazine (MCPP), 0.35 mg/kg
Trial: 7984968
Drug: Interferon alpha-2b
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon alpha-2b treatment (retreatment once or twice)
Trial: 7984968
Drug: Interferon alpha-2b
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon alpha-2b treatment
Trial: 2531910
Drug: mesoglycan (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mesoglycan (150 mg/die i.m. for five days and 144 mg/die per os for a further twenty‐five days)
Trial: 2531910
Drug: dexamethasone (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dexamethasone (24 mg/die i.v. for the first ten days)
Trial: 392744
Drug: Acetard (controlled-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetard (controlled-release acetylsalicylic acid), 1 g X 4 or 2 g X 2 per day
Trial: 392744
Drug: Magnecyl (instant-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnecyl (instant-release acetylsalicylic acid), 1 g X 4 daily
Trial: 30318492
Drug: Pravastatin 10
RxNorm normalized name: pravastatin 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 10 mg per day
Trial: 23683841
Drug: Combined group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined group CBT (eight, 2‐hour weekly sessions) plus individual dilemma‐focused therapy (eight, 1‐hour weekly sessions)
Trial: 23683841
Drug: CBT alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT alone (eight, 2‐hour group weekly sessions plus eight, 1‐hour individual weekly sessions)
Trial: 18321497
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of INHB and AMH
Trial: 17298853
Drug: Paclitaxel 80
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 80 mg/m² plus gemcitabine 1000 mg/m² i.v. on days 1 and 8 with intra-patient alternated dose escalation up to 100 and 1200 mg/m², respectively, over three cycles (arm A)
Trial: 17298853
Drug: Paclitaxel 80
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 80 mg/m² followed by gemcitabine 1000 mg/m² i.v. (100 min) on days 1 and 8 (arm B)
Trial: 11915854
Drug: Alora 0.1
RxNorm normalized name: Alora 0.1mg/24hr Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alora 0.1 mg/day
Trial: 11915854
Drug: Alora 0.05
RxNorm normalized name: Alora 0.05mg/24hr Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alora 0.05 mg/day